← Back to Home

Rectal cancer immunotherapy trial reports 76% complete response rate; surgery avoidance requires separate interpretation

AZUR-1 raises the possibility of organ preservation in rectal cancer with specific molecular features: investigators determined that 68% of evaluable patients maintained a clinical complete response for at least one year without surgery. However, the overall figure of 76% includes postoperative pathology results, and independent review data remain immature.

By SURL BioNews

For patients with rectal cancer, the burden of treatment can persist after the tumor has regressed, affecting bowel, urinary and sexual function. Whether immunotherapy can allow some patients to retain their rectum and reduce the treatment burden is the question the AZUR-1 trial seeks to answer. On October 24, GSK announced that 110 of 144 evaluable patients who received dostarlimab (brand name Jemperli) achieved a complete response, a rate of 76%; however, this figure does not mean that 76% of patients avoided surgery.

This global, multicenter phase 2 trial enrolled 154 previously untreated patients with stage II or III locally advanced rectal cancer, all with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). These tumors have abnormal DNA repair mechanisms, making them more likely to accumulate mutations and more likely to respond to PD-1 blockade. The trial used a single-arm, open-label design, with patients receiving dostarlimab once every three weeks for a total of nine cycles.

The 76% figure comes from an exploratory combined analysis: investigators determined that 98 patients maintained a clinical complete response for at least 12 months without surgery, accounting for 68% of the 144 patients; another 12 patients underwent surgery and had no residual cancer in the resected tissue, constituting a pathological complete response. Both findings show treatment activity, but they answer different questions—the former concerns whether nonsurgical management can be continued, while the latter confirms whether the tumor has disappeared from the resected tissue.

The primary efficacy endpoint requires even closer reading. Independent central review confirmed that 54 of 116 evaluable patients achieved a clinical complete response lasting at least 12 months, a rate of 47%; another 38 patients had achieved a clinical complete response but had not yet completed 12 months of follow-up. This assessment and the investigator-assessed rate of 68% use different evaluable populations, and data are still accumulating, so the two percentages cannot be treated as a direct comparison within the same group of patients. According to ESMO 2026 conference data compiled by OncoDaily, the data cutoff for this analysis was April 20, 2026, and median follow-up was 26.3 months.

Discrepancies between imaging interpretations and tissue findings also affect decisions about organ preservation. FDA data indicate that 15 patients underwent surgery after receiving dostarlimab alone because imaging suggested an incomplete response, yet 12 of them were subsequently confirmed to have a pathological complete response. This suggests that imaging abnormalities after treatment do not necessarily indicate remaining viable cancer cells. It also underscores that nonsurgical management requires a combination of endoscopy, imaging and ongoing follow-up, rather than a decision based on a single examination.

Reducing surgery and chemoradiotherapy still comes with the risks of immunotherapy itself. GSK reported that 20% of patients experienced serious adverse reactions and 3% permanently discontinued treatment because of adverse reactions; common reactions included fatigue, rash, diarrhea and itching. Conference reporting separately listed four patients with grade 3 or higher immune-related adverse events. This is a different measure from “serious adverse reactions,” and the two should not be conflated.

On October 19, the FDA granted accelerated approval to dostarlimab for adults with stage II or III locally advanced rectal cancer confirmed as MSI-H or dMMR by an authorized test. GSK said that, in this AZUR-1 analysis, no recurrence had been reported among patients who achieved a complete response as of the data cutoff; however, a complete response does not mean that a cure has been demonstrated. The trial has no randomized control group, and independent review results have yet to mature. Further data are needed to determine whether organ preservation can be sustained over the long term, recurrence reduced and quality of life improved. The results also cannot be directly generalized to rectal cancers with other molecular profiles.

References

  1. GSK
  2. OncoDaily
  3. FDA
  4. GSK